SG11202104900SA - Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer - Google Patents
Macrocyclic complexes of radionuclides and their use in radiotherapy of cancerInfo
- Publication number
- SG11202104900SA SG11202104900SA SG11202104900SA SG11202104900SA SG11202104900SA SG 11202104900S A SG11202104900S A SG 11202104900SA SG 11202104900S A SG11202104900S A SG 11202104900SA SG 11202104900S A SG11202104900S A SG 11202104900SA SG 11202104900S A SG11202104900S A SG 11202104900SA
- Authority
- SG
- Singapore
- Prior art keywords
- radionuclides
- radiotherapy
- cancer
- macrocyclic complexes
- macrocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862769989P | 2018-11-20 | 2018-11-20 | |
US201962788700P | 2019-01-04 | 2019-01-04 | |
US201962792835P | 2019-01-15 | 2019-01-15 | |
PCT/US2019/062479 WO2020106886A1 (en) | 2018-11-20 | 2019-11-20 | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202104900SA true SG11202104900SA (en) | 2021-06-29 |
Family
ID=70726247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202104900SA SG11202104900SA (en) | 2018-11-20 | 2019-11-20 | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
Country Status (11)
Country | Link |
---|---|
US (5) | US20220016277A1 (en) |
EP (1) | EP3883610A4 (en) |
JP (1) | JP2022507718A (en) |
KR (1) | KR20210116437A (en) |
CN (1) | CN113056288A (en) |
AU (1) | AU2019385497A1 (en) |
CA (1) | CA3119467A1 (en) |
IL (1) | IL283225A (en) |
MX (1) | MX2021005808A (en) |
SG (1) | SG11202104900SA (en) |
WO (1) | WO2020106886A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021013667A (en) * | 2019-05-10 | 2022-01-31 | Janssen Biotech Inc | Macrocyclic chelators and methods of use thereof. |
WO2021250240A1 (en) | 2020-06-12 | 2021-12-16 | Orano | Diaza-18-crown-6 derivative useful for chelating radium, conjugate and radium chelate comprising the same, and uses thereof |
UY39510A (en) * | 2020-11-10 | 2022-05-31 | Janssen Biotech Inc | MACROCYCLIC COMPOUNDS AND METHODS OF USING THEM |
AU2022213825A1 (en) | 2021-01-27 | 2023-09-14 | Janssen Biotech, Inc. | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses |
TW202241526A (en) * | 2021-02-01 | 2022-11-01 | 德商拜耳廠股份有限公司 | Multimeric chelator compounds for use in targeted radiotherapy |
JPWO2022186311A1 (en) * | 2021-03-04 | 2022-09-09 | ||
IL307405A (en) * | 2021-04-02 | 2023-12-01 | Univ Johns Hopkins | Heterobivalent and homobivalent agents targeting fibroblast activation protein alpha and/or prostate-specific membrane antigen |
WO2022251496A1 (en) * | 2021-05-26 | 2022-12-01 | Cornell University | Rigidified macrocycles, complexes with radionuclides, and use in targeted radiotherapy of cancer |
KR20240014479A (en) | 2021-05-27 | 2024-02-01 | 얀센 바이오테크 인코포레이티드 | Compositions and methods for treating prostate cancer |
US11987641B2 (en) | 2021-08-27 | 2024-05-21 | Janssen Biotech, Inc. | Anti-PSMA antibodies and uses thereof |
AU2022354706A1 (en) * | 2021-09-29 | 2024-04-11 | Olivia Newton-John Cancer Research Institute | Macrocycle containing compounds and radiolabelled complexes thereof, as ligands in targeted radiotherapy applications |
WO2023144723A1 (en) | 2022-01-26 | 2023-08-03 | Janssen Biotech, Inc. | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses |
US20230346862A1 (en) | 2022-05-02 | 2023-11-02 | Athanor Biosciences, Inc. | Cancer eradicating - bio-nanoparticles (ce-bnp) |
WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
EP4279092A1 (en) | 2022-05-17 | 2023-11-22 | Bayer AG | Radiopharmaceutical complexes targeting prostate-specific membrane antigen |
WO2023222557A1 (en) | 2022-05-17 | 2023-11-23 | Bayer Aktiengesellschaft | Radiopharmaceutical complexes targeting prostate-specific membrane antigen and its combinations |
CN115304582B (en) * | 2022-07-20 | 2023-05-12 | 北京法伯新天医药科技有限公司 | FAP-alpha specific tumor diagnostic imaging agent |
WO2024026072A1 (en) | 2022-07-28 | 2024-02-01 | Ratio Therapeutics, Inc. | Fibroblast activation protein-targeted compositions and methods of use thereof |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (en) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE |
US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
ES2091684T3 (en) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | THERAPEUTIC APPLICATION OF CHEMICAL AND RADIO-MARKED ANTIBODIES AGAINST THE RESTRICTED DIFFERENTIATION ANTIGEN OF HUMAN B-LYMPHOCYTES FOR THE TREATMENT OF B-CELL LYMPHOMA. |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
EP0951551B9 (en) | 1996-12-23 | 2012-12-26 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
MXPA02001911A (en) | 1999-08-24 | 2003-07-21 | Medarex Inc | Human ctla 4 antibodies and their uses. |
DE60134962D1 (en) | 2000-03-03 | 2008-09-04 | Kyowa Hakko Kogyo Kk | ANTI-CCR4 ANTIBODIES AND FRAGMENTS THEREOF |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
ATE494304T1 (en) | 2000-06-16 | 2011-01-15 | Human Genome Sciences Inc | IMMUNE-SPECIFIC BINDING ANTIBODIES AGAINST BLYS |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
EP1448584B1 (en) | 2001-09-26 | 2010-05-19 | The Government of the United States of America as represented by The Secretary of Health and Human Services | Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells |
DK1562968T3 (en) | 2001-11-14 | 2013-10-28 | Janssen Biotech Inc | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS |
EP1487492A4 (en) | 2002-03-04 | 2008-10-01 | Medimmune Inc | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
ES2362931T3 (en) | 2002-03-04 | 2011-07-15 | Imclone Llc | SPECIFIC HUMAN ANTIBODIES AGAINST KDR AND USES OF THE SAME. |
PT1507556T (en) | 2002-05-02 | 2016-09-28 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
PT3284753T (en) | 2002-10-17 | 2020-05-04 | Genmab As | Human monoclonal antibodies against cd20 |
CA2524305C (en) | 2003-05-01 | 2015-12-08 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
WO2005070967A2 (en) | 2004-01-22 | 2005-08-04 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US7598350B2 (en) | 2004-03-19 | 2009-10-06 | Imclone Llc | Human anti-epidermal growth factor receptor antibody |
IL296666A (en) | 2005-03-23 | 2022-11-01 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
DK2439273T3 (en) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH-1 (PD-1) AND PROCEDURES FOR TREATMENT OF CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNTER APPLICATIONS |
ES2452115T3 (en) | 2005-06-17 | 2014-03-31 | Imclone Llc | An anti-PDGFRalpha antibody for use in the treatment of metastatic bone cancer |
WO2007065027A2 (en) | 2005-12-02 | 2007-06-07 | Dana Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
ES2616355T3 (en) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Antibodies for the human programmed death receptor PD-1 |
EP2033657A1 (en) | 2007-09-04 | 2009-03-11 | Trion Pharma Gmbh | Intraoperative trifunctional antibody application for prophylatic intraperitonal tumour cell dissemination |
HRP20240240T1 (en) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Anti-pd-l1 antibodies and their use to enhance t-cell function |
PL2504364T3 (en) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Targeted binding agents against b7-h1 |
DK2785375T3 (en) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | ANTI-PD-L1 ANTIBODIES AND USES THEREOF |
GB201208309D0 (en) * | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
US20130309234A1 (en) | 2012-05-18 | 2013-11-21 | Trion Pharma Gmbh | Correlation of de novo-induced tumor-associated humoral immune responses with improved clinical outcome |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
EP3029032A1 (en) | 2014-12-05 | 2016-06-08 | Centre National de la Recherche Scientifique (CNRS) | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof |
CN108463229B (en) * | 2016-01-11 | 2023-10-17 | 斯坦福大学托管董事会 | Chimeric proteins and immunotherapeutic methods |
JP7396897B2 (en) * | 2017-04-05 | 2023-12-12 | コーネル ユニバーシティー | Trifunctional constructs with tunable pharmacokinetics useful in imaging and antitumor therapy |
-
2019
- 2019-11-20 US US17/294,375 patent/US20220016277A1/en active Pending
- 2019-11-20 WO PCT/US2019/062479 patent/WO2020106886A1/en unknown
- 2019-11-20 EP EP19887504.9A patent/EP3883610A4/en active Pending
- 2019-11-20 AU AU2019385497A patent/AU2019385497A1/en active Pending
- 2019-11-20 SG SG11202104900SA patent/SG11202104900SA/en unknown
- 2019-11-20 JP JP2021527161A patent/JP2022507718A/en active Pending
- 2019-11-20 US US16/689,856 patent/US11279698B2/en active Active
- 2019-11-20 CN CN201980075936.1A patent/CN113056288A/en active Pending
- 2019-11-20 CA CA3119467A patent/CA3119467A1/en active Pending
- 2019-11-20 MX MX2021005808A patent/MX2021005808A/en unknown
- 2019-11-20 KR KR1020217017495A patent/KR20210116437A/en active Search and Examination
-
2021
- 2021-05-18 IL IL283225A patent/IL283225A/en unknown
-
2022
- 2022-02-23 US US17/678,782 patent/US20220185803A1/en active Pending
- 2022-02-23 US US17/678,793 patent/US20220177461A1/en active Pending
- 2022-02-23 US US17/678,803 patent/US20220274974A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3119467A1 (en) | 2020-05-28 |
US20220016277A1 (en) | 2022-01-20 |
WO2020106886A1 (en) | 2020-05-28 |
AU2019385497A1 (en) | 2021-06-17 |
IL283225A (en) | 2021-07-29 |
US20200157087A1 (en) | 2020-05-21 |
US20220177461A1 (en) | 2022-06-09 |
MX2021005808A (en) | 2021-07-02 |
US20220274974A1 (en) | 2022-09-01 |
US11279698B2 (en) | 2022-03-22 |
EP3883610A1 (en) | 2021-09-29 |
EP3883610A4 (en) | 2022-11-02 |
US20220185803A1 (en) | 2022-06-16 |
JP2022507718A (en) | 2022-01-18 |
KR20210116437A (en) | 2021-09-27 |
CN113056288A (en) | 2021-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283225A (en) | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer | |
IL269763A (en) | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | |
ZA202100195B (en) | Purinone compounds and their use in treating cancer | |
GB201719076D0 (en) | Particles for the treatment of cancer in combination with radiotherapy | |
SI3558997T1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
PT3790879T (en) | Triazolopyrimidine compounds and their use in treating cancer | |
ZA201904966B (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
IL281495A (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
ZA201904967B (en) | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
IL281999A (en) | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer | |
IL254228A0 (en) | Cell therapeutic agent for cancer treatment and combination therapy with same | |
ZA202006008B (en) | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer | |
IL284053A (en) | Novel compounds and their use in therapy | |
IL276768A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
IL261648A (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
IL280617A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
IL274122A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
SG11202007005UA (en) | Use of crassocephalum rabens extract in the treatment of breast cancer | |
SG11202105276TA (en) | Oligo-benzamide analogs and their use in cancer treatment | |
PL3752513T3 (en) | Binuclear palladacycles and their use in the treatment of cancer | |
ZA201900976B (en) | Binuclear palladacycles and their use in the treatment of cancer | |
HK1254107A1 (en) | Anti-trailr2 antibody-toxin-conjugate and use thereof in anti-tumor therapy |